Octagon Capital Advisors LP Arvinas, Inc. Transaction History

Octagon Capital Advisors LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $658,500 - $962,099	10,000 Added 5.93%	178,500 $14.7 Million
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $732,000 - $1.08 Million	-10,000 Reduced 5.6%	168,500 $13.8 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $3.6 Million - $15.2 Million	178,500 New	178,500 $15.2 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.